Fraudulence, Deceptions Coupled With Downright Lies Over MCC950
Evaluation of abiraterone compared with placebo with concurrent prednisone in both arms (COU 302) in prechemotherapy population resulted in improvement of radiographic PFS (co-primary end point) and a strong trend for OS benefit [44]. Median radiographic PFS was 16.5 months in the abiraterone arm and 8.3 months in the placebo arm (HR 0.43; 95% CI 0.35�C0.52; P MCC950 price of docetaxel as first-line chemotherapy dates back to the 1996 FDA approval of the combination of mitoxantrone and prednisone (the comparator arm), demonstrating palliative benefit of this combination, but no survival benefit [56]?and?[57]. Docetaxel is indicated in combination with continuous prednisone for the treatment of patients with androgen-independent MPC [58]. The recommended dose of docetaxel is 75 mg/m2 every 3 weeks as a 1-hour intravenous infusion [58]. The TAX327 phase 3 clinical trial enrolled 1006 men with chemotherapy-naive mCRPC and randomly assigned them to weekly docetaxel for 5 out of 6 weeks or mitoxantrone or docetaxel every 3 weeks [57]. Compared with the men in the mitoxantrone group (OS 16.5 months), patients in the every-3-weeks docetaxel group had an increased OS of 18.9 months, PRDX5 with an HR for death of 0.76 (95% CI 0.62�C0.94; P = 0.009) [57]. Similar benefit in OS was observed in the second trial comparing docetaxel in combination with estamustine with mitoxantrone [12]. The updated extended follow-up survival data from this study showed an absolute median OS of 19.2 months (95% CI 17.5�C21.3 months) in the every-3-weeks docetaxel arm versus 16.3 months (95% CI 14.3�C17.9 months) in the mitoxantrone arm [59]. The management of patients with disease progression during or following docetaxel-based chemotherapy had been a key challenge for oncologists until the approvals of cabazitaxel and abiraterone. Cabazitaxel is a Midostaurin datasheet taxane that exhibits antitumor activity in preclinical models resistant to paclitaxel and docetaxel [60]?and?[61]. In contrast to other taxanes (paclitaxel and docetaxel), cabazitaxel appears to have low affinity for P-glycoprotein, which may contribute to the lack of apparent cross-resistance of cabazitaxel [62]. Cabazitaxel is indicated in combination with prednisone for the treatment of patients with CRPC who previously had failed a docetaxel-based regimen [63]. The FDA-approved dose of cabazitaxel is 25 mg/m2 administered intravenously every 3 weeks over 1 hour in combination with oral prednisone given throughout cabazitaxel treatment [63].
